The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy

Journal of Clinical Virology

Volumn 56, Issue 2, 2013, Pages 102-107

  Enders, Gisela ^a   Daiminger, Anja ^a   Bäder, Ursula ^a   Exler, Simone ^a   Schimpf, Yvonne ^a   Enders, Martin ^a  

^a Institute für Virology Infektiologie und Epidemiologie e V   (Germany)

Author keywords

CMV; IgG avidity; IgG blot; Pregnancy; Serology

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CMV IGG AVIDITY; CYTOMEGALOVIRUS INFECTION; FALSE POSITIVE RESULT; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PREGNANT WOMAN; PRIMARY INFECTION; PRIORITY JOURNAL; RECOMBLOT CMV IGG WITH AVIDITY; RELIABILITY; REPRODUCIBILITY; SECOND TRIMESTER PREGNANCY; SEROCONVERSION; SEROLOGY; THIRD TRIMESTER PREGNANCY;

ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CLINICAL LABORATORY TECHNIQUES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEROLOGIC TESTS; TIME FACTORS;

EID: 84872414845     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.09.015     Document Type: Article

References (21)

1. Stagno S., Pass R.F., Cloud G., Britt W.J., Henderson R.E., Walton P.D., et al. Primary cytomegalovirus infection in pregnancy, incidence, transmission to the fetus and clinical outcome. JAMA 1986, 256:1904-1908.
2. Bodéus M., Kabamba-Mukadi B., Zech F., Hubinont C., Bernard P., Goubau P. Human cytomegalovirus in utero transmission: follow-up of 524 maternal seroconversions. J Clin Virol 2010, 47:201-202.
3. Revello M.G., Fabbri E., Furione M., Zavattoni M., Lilleri D., Tassis B., et al. Role of prenatal diagnosis and counselling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20-year experience. J Clin Virol 2011, 50:303-307.
4. Enders G., Daiminger A., Bäder U., Exler S., Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 2011, 52(3):244-246.
5. Pass R.F., Fowler K.B., Boppana S.B., Britt W.J., Stagno S. Congenital infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 2006, 35:216-220.
6. Daiminger A., Bader U., Enders G. Pre- and periconceptional primary cytomegalovirus infection: risk of vertical transmission and congenital disease. BJOG 2005, 112:166-172.
7. Eggers M., Bäder U., Enders G. Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J Med Virol 2000, 60:324-330.
8. Lazzarotto T., Varani S., Spezzacatena P., Gabrielli L., Pradelli P., Guerra B., et al. Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus. Viral Immunol 2000, 13(1):137-141.
9. Grangeot-Keros L., Baccard-Longere M., Freymuth F., Cointe D., Seigneurin J.M. Multicenter evaluation of a rapid and convenient method for determination of cytomegalovirus immunoglobulin G avidity. Clin Diagn Lab Immunol 2001, 8(2):429-431.
10. Mace M., Sissoeff L., Rudent A., Grangeot-Keros L. A serological testing algorithm for the diagnosis of primary CMV infection in pregnant women. Prenat Diagn 2004, 24(11):861-863.
11. Bodeus M., Beulne D., Goubau P. Ability of three IgG-avidity assays to exclude recent cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2001, 20(4):248-252.
12. Bodeus M., Van Ranst M., Bernard P., Hubinont C., Goubau P. Anticytomegalovirus IgG avidity in pregnancy: a 2-year prospective study. Fetal Diagn Ther 2002, 17(6):362-366.
13. Eggers M., Metzger C., Enders G. Differentiation between acute primary and recurrent human cytomegalovirus infection in pregnancy, using a microneutralization assay. J Med Virol 1998, 56:351-358.
14. Schoppel K., Kropff B., Schmidt C., Vornhagen R., Mach M. The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 1997, 175(3):533-544.
15. Eggers M., Radsak K., et al. Use of recombinant glycoprotein antigen gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy. J Med Virol 2001, 63(2):135-142.
16. Nigro G., Adler S.P., La Torre R., Best A.M., Congenital Cytomegalovirus Collaborating Group Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353:1350-1362.
17. Dangel V., Bader U., Enders G. Improvement of cytomegalovirus avidity testing by adjusting the concentration of CMV-specific IgG in test samples. J Clin Virol 2005, 35(3):303-309.
18. Dollard S.C., Staras S.A., Amin M.M., Schmid D.S., Cannon M.J. National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity. Clin Vaccine Immunol 2011, 18(11):1895-1899.
19. Revello M.G., Genini E., Gorini G., Klersy C., Pialla A., Gerna G. Comparative evaluation of eight commercial human cytomeglovirus IgG avidity assays. J Clin Virol 2010, 48:255-259.
20. Maine G.T., Stricker R., Stricker R. Kinetics of CMV seroconversion in a Swiss pregnant women population. Diagn Microbiol Infect Dis 2012, 73(3):275-277.
21. Kanengisser-Pines B., Hazan Y., Pines G., Appelman Z. High cytomegalovirus IgG avidity is a reliable indicator of past infection in patients with positive IgM detected during the first trimester of pregnancy. J Perinat Med 2009, 37(1):15-18.